Antibody-mediated remyelination: Relevance to multiple sclerosis

A. J. Bieber, K. Asakura, A. Warrington, S. V. Kaveri, M. Rodriguez

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Intravenous immunoglobulin (IVIG) is widely used for treatment of autoimmune neurological disorders and is currently in clinical trials as a therapy for multiple sclerosis. We have previously demonstrated that certain mouse monoclonal antibodies of the IgM isotype, promote significant remyelination when administered to mice with chronic Theiler's murine encephalomyelitis virus-induced demyelinating disease. These IgM antibodies bind to antigens expressed on oligodendrocytes. We now demonstrate that polyclonal human IgG (IVIG) and polyclonal human IgM also promote remyelination in this system. Although both polyclonal human IgG and IgM promote remyelination, IgM is more potent. Polyclonal human IgM also differs from human IgG in its ability to bind strongly antigens expressed in the CNS and by oligodendrocytes. We propose that polyclonal IgG and polyclonal IgM may function to promote remyelination by different mechanisms. IVIG may function based on its immunomodulatory activity, while the activity of IgM is critically dependent upon its reactivity with CNS antigens. This possibility has clear relevance to the use of antibodies as a therapy for multiple sclerosis, suggesting that combined treatment with antibodies exerting immunomodulatory activity, in concert with antibodies that function through direct binding to CNS antigens, may synergize to enhance the efficacy of the therapy.

Original languageEnglish (US)
JournalMultiple Sclerosis
Volume6
Issue numberSUPPL. 2
StatePublished - 2000

Fingerprint

Multiple Sclerosis
Immunoglobulin M
Antibodies
Intravenous Immunoglobulins
Immunoglobulin G
Antigens
Oligodendroglia
Theilovirus
Demyelinating Diseases
Nervous System Diseases
Therapeutics
Monoclonal Antibodies
Clinical Trials

Keywords

  • Immunoglobulin
  • Multiple sclerosis
  • Oligodendrocyte
  • Remyelination
  • Theiler's virus

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Bieber, A. J., Asakura, K., Warrington, A., Kaveri, S. V., & Rodriguez, M. (2000). Antibody-mediated remyelination: Relevance to multiple sclerosis. Multiple Sclerosis, 6(SUPPL. 2).

Antibody-mediated remyelination : Relevance to multiple sclerosis. / Bieber, A. J.; Asakura, K.; Warrington, A.; Kaveri, S. V.; Rodriguez, M.

In: Multiple Sclerosis, Vol. 6, No. SUPPL. 2, 2000.

Research output: Contribution to journalArticle

Bieber, AJ, Asakura, K, Warrington, A, Kaveri, SV & Rodriguez, M 2000, 'Antibody-mediated remyelination: Relevance to multiple sclerosis', Multiple Sclerosis, vol. 6, no. SUPPL. 2.
Bieber AJ, Asakura K, Warrington A, Kaveri SV, Rodriguez M. Antibody-mediated remyelination: Relevance to multiple sclerosis. Multiple Sclerosis. 2000;6(SUPPL. 2).
Bieber, A. J. ; Asakura, K. ; Warrington, A. ; Kaveri, S. V. ; Rodriguez, M. / Antibody-mediated remyelination : Relevance to multiple sclerosis. In: Multiple Sclerosis. 2000 ; Vol. 6, No. SUPPL. 2.
@article{b270bc3cd7324623a90a244051092e87,
title = "Antibody-mediated remyelination: Relevance to multiple sclerosis",
abstract = "Intravenous immunoglobulin (IVIG) is widely used for treatment of autoimmune neurological disorders and is currently in clinical trials as a therapy for multiple sclerosis. We have previously demonstrated that certain mouse monoclonal antibodies of the IgM isotype, promote significant remyelination when administered to mice with chronic Theiler's murine encephalomyelitis virus-induced demyelinating disease. These IgM antibodies bind to antigens expressed on oligodendrocytes. We now demonstrate that polyclonal human IgG (IVIG) and polyclonal human IgM also promote remyelination in this system. Although both polyclonal human IgG and IgM promote remyelination, IgM is more potent. Polyclonal human IgM also differs from human IgG in its ability to bind strongly antigens expressed in the CNS and by oligodendrocytes. We propose that polyclonal IgG and polyclonal IgM may function to promote remyelination by different mechanisms. IVIG may function based on its immunomodulatory activity, while the activity of IgM is critically dependent upon its reactivity with CNS antigens. This possibility has clear relevance to the use of antibodies as a therapy for multiple sclerosis, suggesting that combined treatment with antibodies exerting immunomodulatory activity, in concert with antibodies that function through direct binding to CNS antigens, may synergize to enhance the efficacy of the therapy.",
keywords = "Immunoglobulin, Multiple sclerosis, Oligodendrocyte, Remyelination, Theiler's virus",
author = "Bieber, {A. J.} and K. Asakura and A. Warrington and Kaveri, {S. V.} and M. Rodriguez",
year = "2000",
language = "English (US)",
volume = "6",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Antibody-mediated remyelination

T2 - Relevance to multiple sclerosis

AU - Bieber, A. J.

AU - Asakura, K.

AU - Warrington, A.

AU - Kaveri, S. V.

AU - Rodriguez, M.

PY - 2000

Y1 - 2000

N2 - Intravenous immunoglobulin (IVIG) is widely used for treatment of autoimmune neurological disorders and is currently in clinical trials as a therapy for multiple sclerosis. We have previously demonstrated that certain mouse monoclonal antibodies of the IgM isotype, promote significant remyelination when administered to mice with chronic Theiler's murine encephalomyelitis virus-induced demyelinating disease. These IgM antibodies bind to antigens expressed on oligodendrocytes. We now demonstrate that polyclonal human IgG (IVIG) and polyclonal human IgM also promote remyelination in this system. Although both polyclonal human IgG and IgM promote remyelination, IgM is more potent. Polyclonal human IgM also differs from human IgG in its ability to bind strongly antigens expressed in the CNS and by oligodendrocytes. We propose that polyclonal IgG and polyclonal IgM may function to promote remyelination by different mechanisms. IVIG may function based on its immunomodulatory activity, while the activity of IgM is critically dependent upon its reactivity with CNS antigens. This possibility has clear relevance to the use of antibodies as a therapy for multiple sclerosis, suggesting that combined treatment with antibodies exerting immunomodulatory activity, in concert with antibodies that function through direct binding to CNS antigens, may synergize to enhance the efficacy of the therapy.

AB - Intravenous immunoglobulin (IVIG) is widely used for treatment of autoimmune neurological disorders and is currently in clinical trials as a therapy for multiple sclerosis. We have previously demonstrated that certain mouse monoclonal antibodies of the IgM isotype, promote significant remyelination when administered to mice with chronic Theiler's murine encephalomyelitis virus-induced demyelinating disease. These IgM antibodies bind to antigens expressed on oligodendrocytes. We now demonstrate that polyclonal human IgG (IVIG) and polyclonal human IgM also promote remyelination in this system. Although both polyclonal human IgG and IgM promote remyelination, IgM is more potent. Polyclonal human IgM also differs from human IgG in its ability to bind strongly antigens expressed in the CNS and by oligodendrocytes. We propose that polyclonal IgG and polyclonal IgM may function to promote remyelination by different mechanisms. IVIG may function based on its immunomodulatory activity, while the activity of IgM is critically dependent upon its reactivity with CNS antigens. This possibility has clear relevance to the use of antibodies as a therapy for multiple sclerosis, suggesting that combined treatment with antibodies exerting immunomodulatory activity, in concert with antibodies that function through direct binding to CNS antigens, may synergize to enhance the efficacy of the therapy.

KW - Immunoglobulin

KW - Multiple sclerosis

KW - Oligodendrocyte

KW - Remyelination

KW - Theiler's virus

UR - http://www.scopus.com/inward/record.url?scp=0033758185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033758185&partnerID=8YFLogxK

M3 - Article

C2 - 11188771

AN - SCOPUS:0033758185

VL - 6

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - SUPPL. 2

ER -